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Regulation of mTOR function in response to hypoxia by REDD1
and the TSC1/TSC2 tumor suppressor complex
Abstract
Mammalian target of rapamycin (mTOR) is a central regulator of protein synthesis whose activity is
modulated by a variety of signals. Energy depletion and hypoxia result in mTOR inhibition. While
energy depletion inhibits mTOR through a process involving the activation of AMP-activated protein
kinase (AMPK) by LKB1 and subsequent phosphorylation of TSC2, the mechanism of mTOR inhibition
by hypoxia is not known. Here we show that mTOR inhibition by hypoxia requires the TSC1/TSC2
tumor suppressor complex and the hypoxia-inducible gene REDD1/RTP801. Disruption of the
TSC1/TSC2 complex through loss of TSC1 or TSC2 blocks the effects of hypoxia on mTOR, as
measured by changes in the mTOR targets S6K and 4E-BP1, and results in abnormal accumulation of
Hypoxia-inducible factor (HIF). In contrast to energy depletion, mTOR inhibition by hypoxia does not
require AMPK or LKB1. Down-regulation of mTOR activity by hypoxia requires de novo mRNA
synthesis and correlates with increased expression of the hypoxia-inducible REDD1 gene. Disruption of
REDD1 abrogates the hypoxia-induced inhibition of mTOR, and REDD1 overexpression is sufficient to
down-regulate S6K phosphorylation in a TSC1/TSC2-dependent manner. Inhibition of mTOR function
by hypoxia is likely to be important for tumor suppression as TSC2-deficient cells maintain abnormally
high levels of cell proliferation under hypoxia.
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Mammalian target of rapamycin (mTOR) is a central regulator of protein synthesis whose activity is
modulated by a variety of signals. Energy depletion and hypoxia result in mTOR inhibition. While energy
depletion inhibits mTOR through a process involving the activation of AMP-activated protein kinase (AMPK)
by LKB1 and subsequent phosphorylation of TSC2, the mechanism of mTOR inhibition by hypoxia is not
known. Here we show that mTOR inhibition by hypoxia requires the TSC1/TSC2 tumor suppressor complex
and the hypoxia-inducible gene REDD1/RTP801. Disruption of the TSC1/TSC2 complex through loss of TSC1
or TSC2 blocks the effects of hypoxia on mTOR, as measured by changes in the mTOR targets S6K and
4E-BP1, and results in abnormal accumulation of Hypoxia-inducible factor (HIF). In contrast to energy
depletion, mTOR inhibition by hypoxia does not require AMPK or LKB1. Down-regulation of mTOR activity
by hypoxia requires de novo mRNA synthesis and correlates with increased expression of the
hypoxia-inducible REDD1 gene. Disruption of REDD1 abrogates the hypoxia-induced inhibition of mTOR, and
REDD1 overexpression is sufficient to down-regulate S6K phosphorylation in a TSC1/TSC2-dependent
manner. Inhibition of mTOR function by hypoxia is likely to be important for tumor suppression as
TSC2-deficient cells maintain abnormally high levels of cell proliferation under hypoxia.
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Tuberous sclerosis complex, a disease characterized by
benign tumors in multiple tissues, results from muta-
tions in either Tuberous Sclerosis Complex 1 (Tsc1) or 2
(Tsc2) (Cheadle et al. 2000). Tsc1 (also called hamartin)
and Tsc2 (also called tuberin) form a protein complex
(van Slegtenhorst et al. 1998) that integrates signals from
a variety of sources, including growth factors (Gao and
Pan 2001; Potter et al. 2001; Tapon et al. 2001) and en-
ergy stores (Inoki et al. 2003b), with the protein transla-
tion apparatus. Tsc2 functions as a GTPase-activating
protein (GAP) toward the small G protein Rheb, which
through a poorly understood mechanism controls mam-
malian target of rapamycin (mTOR), a central regulator
of protein translation (Castro et al. 2003; Garami et al.
2003; Inoki et al. 2003a; Saucedo et al. 2003; Stocker et
al. 2003; Tee et al. 2003; Y. Zhang et al. 2003).
Regulation of mTOR by growth factors has been in-
tensively studied. In response to growth factor stimula-
tion, phosphatidylinositol 3-kinase (PI3K) is activated,
leading to the generation of phosphatidylinositol-3,4,5-
triphosphate and the recruitment of Akt to the plasma
membrane where it is activated by phosphorylation
(Cantley 2002). Akt is a serine/threonine kinase that
phosphorylates many effectors including Tsc2 (Dan et al.
2002; Inoki et al. 2002; Manning et al. 2002; Potter et al.
2002). The mechanism whereby Akt phosphorylation
regulates Tsc2 function is controversial, but it is thought
ultimately to lead to its inactivation, thereby allowing
the accumulation of Rheb-GTP and the activation of
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mTOR. In support of the idea that Tsc1/Tsc2 plays a
critical role in mTOR regulation by growth factors, cells
deficient for Tsc1 or Tsc2 fail to down-regulate mTOR
function in response to growth factor deprivation (Gao et
al. 2002; Inoki et al. 2002; Jaeschke et al. 2002; Kwiat-
kowski et al. 2002; H. Zhang et al. 2003).
Recent studies have also shed light on how Tsc1/Tsc2
regulates mTOR function in response to changes in en-
ergy availability. AMP-activated protein kinase (AMPK)
is a master regulator of energy metabolism that is acti-
vated in response to energy deprivation (Carling 2004).
AMPK functions as a serine/threonine kinase and di-
rectly phosphorylates Tsc2 (Inoki et al. 2003b). Cells de-
ficient for Tsc1/Tsc2, or producing a TSC2 variant that
can not be phosphorylated by AMPK, fail to down-regu-
late mTOR in situations of energy deprivation (Inoki et
al. 2003b). Signaling by energy depletion also involves
the Lkb1 tumor suppressor protein, which is inactivated
in Peutz-Jeghers syndrome. Lkb1 is a serine/threonine
kinase that phosphorylates a variety of substrates, in-
cluding AMPK (Hawley et al. 2003; Woods et al. 2003;
Shaw et al. 2004b). AMPK activation with consequent
Tsc1/Tsc2-mediated inhibition of mTOR by energy
depletion requires Lkb1 (Corradetti et al. 2004; Shaw et
al. 2004b). Thus under conditions that are adverse for
growth, such as in the presence of reduced energy stores,
mTOR function is inhibited, thereby down-regulating
protein synthesis and conserving energy.
mTOR function is also regulated by amino acid avail-
ability (Gingras et al. 2001). Whereas mTOR regulation
by growth factors and energy stores requires an intact
Tsc1/Tsc2 complex, amino acids seem to regulate
mTOR function through both Tsc1/Tsc2-dependent and
independent pathways (Gao et al. 2002; H. Zhang et al.
2003).
mTOR is a conserved serine/threonine kinase that
phosphorylates a series of substrates involved in protein
translation including 4E-BP1 and S6K (Gingras et al.
2001). 4E-BP1 binds the translation initiation factor eIF-
4E, preventing its interaction with other members of the
eIF-4 complex and thereby inhibiting translation initia-
tion of 5 cap (7-methyl GTP) mRNAs. 4E-BP1 phos-
phorylation by mTOR, as well as other kinases in the
PI3K pathway, relieves this inhibition, thereby promot-
ing mRNA translation (Gingras et al. 2001).
In mammals, there are two S6K genes, S6K1 and S6K2,
and each has two different splice forms. While S6K2 and
the long form (∼85 kDa) of S6K1 localize to the nucleus,
the short form of S6K1 (∼70 kDa) is cytoplasmic. S6K is
thought to exist in an inactive, closed conformation, re-
sulting from an intramolecular interaction between the
catalytic domain and a pseudosubstrate domain (Fingar
and Blenis 2004). There are at least eight phosphoryla-
tion sites in S6K1 and its activation requires a complex
process of phosphorylation involving mTOR as well as
other PI3K effectors. Phosphorylation in the linker re-
gion, at Ser 371 and Thr 389, is essential for S6K1 acti-
vation (Dufner and Thomas 1999). Thr 389 is the major
rapamycin-sensitive site and can be phosphorylated by
mTOR in vitro, suggesting that it is a direct mTOR tar-
get (Dufner and Thomas 1999). Phosphorylation at this
site has also been shown to be regulated in response to
changes in Tsc1/Tsc2 levels (Inoki et al. 2002; Jaeschke
et al. 2002; Kwiatkowski et al. 2002; Manning et al.
2002; H. Zhang et al. 2003).
The best-characterized substrate of S6K1 is the ribo-
somal protein S6. S6 is an integral component of the 40S
subunit that is required for cell proliferation but whose
precise function is unclear (Volarevic et al. 2000). S6 is
thought to be regulated primarily through successive
phosphorylation events beginning at S236 and S235.
Phosphorylation at these sites is rapamycin-sensitive
and largely mediated by S6K (Dufner and Thomas 1999).
Indeed, cells deficient for both S6K1 and S6K2 have pro-
foundly reduced levels of S6 S235/236 phosphorylation
(Pende et al. 2004). Thus, S235/236 phosphorylation pro-
vides an accurate readout for endogenous S6K activity.
The Hypoxia-inducible factor (Hif) has also been
shown to be regulated by mTOR (Hudson et al. 2002).
Hif is a heterodimeric transcription factor composed of a
stable  and a labile  subunit whose levels are con-
trolled by oxygen tension (Semenza 2000). In the pres-
ence of oxygen, Hif- subunits are hydroxylated at spe-
cific prolyl residues and targeted for degradation by an E3
ubiquitin ligase that contains the von Hippel-Lindau tu-
mor suppressor protein (pVHL) (Kaelin 2002). pVHL in-
activation in patients with von Hippel-Lindau disease
results in Hif up-regulation and the development of tu-
mors. As in pVHL-deficient cells, Tsc2-deficient cells
harbor increased levels of Hif- relative to wild-type
cells, especially under growth factor poor conditions
(Brugarolas et al. 2003). Hif up-regulation in Tsc2-defi-
cient cells is likely to result from increased mTOR ac-
tivity as mTOR increases Hif stability and increased Hif
levels in Tsc2-deficient cells can be normalized by treat-
ment with rapamycin (Hudson et al. 2002; Brugarolas et
al. 2003).
It was recently shown that mTOR function is regu-
lated by hypoxia (Arsham et al. 2003). Hypoxia down-
regulates 4E-BP1 phosphorylation and increases 4E-BP1
binding to eIF-4E at 5 cap structures. Similarly, hypoxia
down-regulates S6K phosphorylation at multiple sites
including T389 and inhibits S6 phosphorylation. Hy-
poxia-induced inhibition of mTOR is dominant over
mTOR activating signals from growth factors and nutri-
ents and occurs independently of Hif-1 (Arsham et al.
2003). However, how mTOR function is regulated by
hypoxia is not known.
Here we show that mTOR inhibition by hypoxia re-
quires an intact Tsc1/Tsc2 complex. Furthermore,
down-regulation of mTOR function by hypoxia requires
de novo transcription and the expression of the hypoxia-
inducible Redd1/RTP801 gene.
Results
Tsc1/Tsc2 complex is required for mTOR regulation
by hypoxia
To examine the contribution of the Tsc1/Tsc2 complex
to the regulation of mTOR function by hypoxia, the ef-
Brugarolas et al.
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fects of hypoxia on MEFs derived from Tsc2-deficient
embryos were analyzed. Loss of Tsc2 results in lethality
at approximately day 10.5 of gestation when it is diffi-
cult to obtain a large number of fibroblasts (Rennebeck
et al. 1998). To extend the life span of the few fibroblasts
that can be obtained from these embryos, mice were in-
tercrossed with mice carrying mutations in p53, which
enhances the life span of the limited number of MEFs
that can be obtained (H. Zhang et al. 2003). In the ex-
periments that follow, Tsc2−/−;p53−/− MEFs were com-
pared with Tsc2+/+;p53−/− MEFs. For simplicity, these
MEFs are referred to as “Tsc2−/−” and “Tsc2+/+,” respec-
tively.
Tsc1/Tsc2 complex regulates mTOR in response to
growth factors. As shown before, serum deprivation in-
hibits mTOR, as evidenced by decreased phosphoryla-
tion of the mTOR effector S6K (T389) (Fig. 1A). S6K
T389 is the major rapamycin-sensitive site and is re-
quired for S6K activity (Dufner and Thomas 1999). The
down-regulation of S6K phosphorylation is associated
with a decrease in S6 phosphorylation (S235/236). We
also confirmed that mTOR inhibition by serum depri-
vation requires an intact Tsc1/Tsc2 complex and is
abrogated in Tsc2−/− MEFs (Fig. 1A) (Jaeschke et al. 2002;
H. Zhang et al. 2003). Rapamycin inhibits S6K phos-
phorylation and activity regardless of Tsc2 status, sup-
porting the concept that Tsc1/Tsc2 functions upstream
of mTOR (Fig. 1A).
Tsc2+/+ MEFs down-regulated S6K phosphorylation
and activity in response to hypoxia (Fig. 1A), in keeping
with an earlier study using transformed human embry-
onic kidney (HEK293) cells (Arsham et al. 2003). Down-
regulation of S6 phosphorylation in response to hy-
poxia was also demonstrable in mice exposed to 6% oxy-
gen, suggesting that this phenomenon is not restricted to
tissue culture (Supplementary Fig. 1). In contrast, hy-
poxia failed to down-regulate S6K and S6 phosphoryla-
tion in Tsc2−/− MEFs (Fig. 1A) and Tsc1−/− mouse 3T3
cells (Fig. 1B), indicating that mTOR inhibition by hy-
poxia requires an intact Tsc1/Tsc2 complex. Likewise
hypoxia promoted the binding of 4E-BP1 to 7-methyl
GTP (7mGTP) in Tsc2+/+ cells but not Tsc2−/− cells, con-
sistent with Tsc2-dependent inhibition of 4E-BP1 phos-
phorylation by mTOR in response to hypoxia (Fig. 1C).
Taken together, these data indicate that mTOR inhibi-
tion by hypoxia requires a functional Tsc1/Tsc2 com-
plex.
We previously showed that Hif- (hereafter referred to
as Hif) levels are regulated in response to growth factors
through a mechanism that involves the Tsc1/Tsc2 com-
plex and mTOR (Brugarolas et al. 2003; see also Fig. 1A).
As Tsc2−/− MEFs failed to down-regulate mTOR activity
in response to hypoxia, we postulated that Hif levels
might also be affected. Tsc2−/− MEFs were not impaired
in the up-regulation of Hif in response to hypoxia. How-
ever, whereas Tsc2+/+ MEFs down-regulated Hif with
prolonged hypoxia, Hif levels remained elevated in
Tsc2−/− MEFs (Fig. 1D). Consistent with the idea that
increased Hif levels in Tsc2−/− cells under prolonged hy-
poxia result from increased mTOR activity, treatment
Figure 1. Tsc2 regulates mTOR in response to hypoxia. (A) Western blot analysis of Tsc2+/+ and Tsc2−/− MEFs. (Hif) Hif-1 and/or
Hif-2; (S6K-P) S6K phosphorylated T389; (S6-P) S6 phosphorylated on S235/236. Left panel shows MEF in 0.05% serum or following
serum addition (10% serum for 45 min) pretreated or not with rapamycin (1.5 h prior to serum addition). Right panel shows MEFs
exposed to hypoxia for the indicated periods of time. (B) Western blot analysis of Tsc1+/+ and Tsc1−/− mouse 3T3 cells treated with
hypoxia for the indicated periods of time. (C) Western blot analysis of input (left) and 7mGTP-bound (right) proteins from extracts of
Tsc2+/+ and Tsc2−/− MEFs exposed to hypoxia for the indicated periods of time. (D,E) Western blot analysis of extracts from Tsc2+/+ and
Tsc2−/− MEFs exposed to hypoxia for the indicated periods of time. In E all the cells were treated with rapamycin for 26 h prior to lysis
regardless of the duration of hypoxia.
Hypoxia regulation of mTOR by REDD1 and TSC1/TSC2
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with rapamycin restored the down-regulation of Hif nor-
mally observed after prolonged hypoxia (Fig. 1E).
The importance of Tsc2 in the regulation of mTOR by
hypoxia is further supported by reconstitution experi-
ments. Tsc2−/− MEFs were infected with a retrovirus en-
coding epitope-tagged human Tsc2. Retrovirally trans-
duced Tsc2−/− MEFs achieved Tsc2 protein levels that
were similar to endogenous levels in Tsc2+/+ MEFs (Fig.
2A). Reintroduction of Tsc2 into Tsc2−/− MEFs restored
the down-regulation of S6 phosphorylation by hypoxia
(Fig. 2A).
To determine the generalizability of our observations,
the role of Tsc2 in mTOR regulation by hypoxia was
examined in other cell types. Tsc2 knockdown with two
different Tsc2 siRNAs in HEK293 and HeLa cervical car-
cinoma cells blocked the down-regulation of S6 phos-
phorylation by hypoxia (Fig. 2B; Supplementary Fig. 2),
indicating that Tsc2 is required for mTOR regulation by
hypoxia in multiple cell types.
Tsc2 inactivation confers a proliferative advantage
under hypoxia
Taken together, these data establish the importance of
Tsc1/Tsc2 in the regulation of mTOR by hypoxia. As
Tsc1/Tsc2 functions as a tumor suppressor, we asked
whether disruption of this complex would affect cell pro-
liferation under hypoxic conditions. In keeping with pre-
vious observations, the rates of cell proliferation of
Tsc2−/− and Tsc2+/+ MEFs were very similar under nor-
moxic conditions for several days (Fig. 3A; H. Zhang et
al. 2003). After 4 d in culture the rate of proliferation of
Tsc2+/+ cells began to decline relative to Tsc2−/− cells,
possibly due to depletion of nutrients and growth factors
from the media. Consistent with this idea, Tsc2−/− but
not Tsc2+/+ MEFs proliferate under conditions of serum
deprivation (H. Zhang et al. 2003). We next measured the
proliferation of Tsc2−/− and Tsc2+/+ cells under hypoxic
conditions. To avoid confounding effects from media
depletion, the media was changed daily. Under hypoxic
conditions Tsc2−/− MEFs exhibited a marked prolifera-
tive advantage compared with Tsc2+/+ MEFs (Fig. 3B).
Increased proliferation of Tsc2−/− MEFs under hypoxic
conditions correlated with persistently elevated levels
of S6 phosphorylation (Fig. 3C) and was abrogated by
treatment with rapamycin (Fig. 3B). These data suggest
that failure to down-regulate mTOR in response to hy-
poxia in Tsc2−/− MEFs confers a growth advantage that
might contribute to tumor formation in TSC patients. It
should be noted that the growth inhibitory effect of hy-
poxia on Tsc2+/+ MEFs in these assays is p53 indepen-
dent since both the Tsc2+/+ and Tsc2−/− MEFs used here
lack p53.
Tsc1/Tsc2 regulation by hypoxia is AMPK
and Lkb1 independent
Energy depletion results in Tsc1/Tsc2-mediated mTOR
inhibition through a mechanism that involves Lkb1 and
AMPK (Inoki et al. 2003b; Corradetti et al. 2004; Shaw et
al. 2004a). Since hypoxia might also affect cellular en-
ergy stores, we sought to determine whether hypoxia
regulated mTOR through a similar pathway. AICAR (5-
aminoomidazole-4-carboxyamide), a cell-permeable
AMPK agonist, inhibited mTOR and down-regulated S6
phosphorylation (Fig. 4A; Kimura et al. 2003). As previ-
ously reported (Shaw et al. 2004b), Tsc2−/− cells failed to
down-regulate S6 phosphorylation in response to AICAR
despite robust activation of AMPK as determined by
AMPK phosphorylation in the T loop and the phosphory-
lation of its substrate acetyl-CoA carboxylase (ACC) (Fig.
4A), thereby justifying the use of AICAR as an AMPK
perturbant in the experiments described below.
To ask whether hypoxia signals are transduced
through an energy depletion pathway in our system, we
first examined the effects of hypoxia on AMPK activity.
After 4 h of hypoxia, S6 phosphorylation was markedly
down-regulated without a detectable increase in AMPK
activity, as measured by ACC phosphorylation (Fig. 4B).
The ability to detect ACC phosphorylation in response
to AMPK activation was confirmed by studying cells
treated with AICAR in parallel (Fig. 4B). Furthermore, in
vitro kinase assays with AMPK immunoprecipitates
from the same lysates used for Figure 4B indicated that
hypoxia, in contrast to AICAR, did not increase and may
have decreased AMPK kinase activity (Fig. 4C). These
results are consistent with a recent study of HEK293
cells exposed to hypoxia for 30 min (Arsham et al. 2003).
We next asked whether AMPK activity is necessary for
Figure 2. Tsc2 is both necessary and sufficient for the regula-
tion of S6 phosphorylation by hypoxia. (A) Western blot analysis
of Tsc2−/− MEFs retrovirally transduced with either a Tsc2 ex-
pression vector or an empty vector and treated with hypoxia for
the indicated periods of time. Tsc2+/+ MEFs are included as con-
trols. (B) Western blot analysis of HEK293 cells transfected with
two different synthetic Tsc2 siRNAs (a and b) or a scrambled
siRNA (Sc) and exposed to hypoxia for the indicated periods of
time.
Brugarolas et al.
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the hypoxia-induced down-regulation of mTOR func-
tion. Pharmacological inhibition of AMPK with com-
pound C (Inoki et al. 2003b) at doses sufficient to block
the down-regulation of S6 phosphorylation by AICAR
did not block the down-regulation of S6 phosphorylation
by hypoxia (Fig. 4D). Thus AMPK is required for AICAR
signaling but not for hypoxia signaling.
Next we examined the requirements for the AMPK
kinase Lkb1. Consistent with previous studies, Lkb1−/−
MEFs failed to down-regulate S6 phosphorylation in re-
sponse to AICAR (Fig. 4E; Shaw et al. 2004b). In contrast,
we found that Lkb1 loss did not affect the down-regula-
tion of S6 phosphorylation by hypoxia (Fig. 4F). In addi-
tion, HeLa cells, which are defective for Lkb1 (Tiainen et
al. 1999), also down-regulated S6 phosphorylation in re-
sponse to hypoxia but not to AICAR (Supplementary Fig.
3) indicating that Lkb1, like AMPK, is dispensable for
hypoxia signaling. We noted, however, that ACC and
AMPK do become phosphorylated in HeLa cells after
prolonged hypoxia, possibly due to a non-Lkb1 AMPK
kinase (Supplementary Fig. 3). Nonetheless, inhibition of
S6 phosphorylation occurred prior to appreciable AMPK
activation in these cells, again in keeping with the idea
that the acute down-regulation of mTOR in response to
hypoxia is AMPK independent. It is possible that signal-
ing to Tsc1/Tsc2 in response to chronic hypoxia involves
both Lkb1/AMPK-dependent and independent pathways
since prolonged hypoxia would predictably lead to ATP
depletion and accumulation of AMP.
Regulation of mTOR by hypoxia requires
Redd1 induction
To begin to unravel the signaling pathway whereby hy-
poxia regulates Tsc1/Tsc2, we asked whether this
mechanism required de novo transcription. Provoca-
tively, inhibition of transcription with actinomycin D
blocked the down-regulation of S6 phosphorylation by
hypoxia, indicating that de novo transcription is neces-
sary for hypoxia signaling (Fig. 5A). As a control actino-
mycin D alone did not affect baseline S6 phosphoryla-
tion (Fig. 5A).
Recently, the Drosophila ortholog of the hypoxia-in-
ducible Redd1 gene was isolated in a screen for suppres-
sors of insulin signaling (Reiling and Hafen 2004). Redd1
was originally identified by several groups as a gene that
is induced at the mRNA level in response to stresses
such as hypoxia or DNA damage (Ellisen et al. 2002;
Shoshani et al. 2002). Redd1 encodes a protein with a
predicted MW of 25 kDa that lacks any known func-
tional domains (Ellisen et al. 2002; Shoshani et al. 2002).
Redd1 belongs to a family of highly conserved proteins
that includes Redd2, which might also be regulated by
hypoxia (Cuaz-Perolin et al. 2004). Redd orthologs have
been shown to inhibit insulin signaling in Drosophila
and epistasis analysis suggests that they act upstream of
Tsc1/Tsc2 (Reiling and Hafen 2004).
To ascertain whether Redd1 was involved in the regu-
lation of the mTOR by hypoxia, we first examined Redd1
induction in response to hypoxia in MEFs. Consistent
with previous data, Redd1 mRNA levels were induced
by hypoxia (Fig. 5B; Shoshani et al. 2002). Redd2 expres-
sion, however, was not detected in MEFs (data not shown).
To ask whether Redd1 is necessary for hypoxia-in-
duced down-regulation of mTOR function, we obtained
Redd1−/− MEFs (K. Lei and L.W. Ellisen, in prep.). In con-
trast to Redd1+/+ MEFs, Redd1−/− MEFs failed to down-
regulate phosphorylation of S6K and S6 in response to
hypoxia (Fig. 5C). These data indicate that Redd1, like
Tsc1 and Tsc2, is necessary for the hypoxia-induced
down-regulation of mTOR signaling. This requirement
was specific because Redd1−/− MEFs, in contrast to
Tsc2−/− MEFs, down-regulated S6 phosphorylation in re-
sponse to serum deprivation (Fig. 6A,B). These data in-
dicate that Redd1 regulates mTOR signaling only in re-
sponse to certain stimuli, such as hypoxia.
Redd1 is sufficient to down-regulate
S6K1 phosphorylation
We next asked whether Redd1 is sufficient to down-regu-
late mTOR function. For this purpose, the effects of
Redd1 expression on S6K phosphorylation were deter-
mined. HEK293 cells were transfected with HA-tagged
Figure 3. Tsc2 loss confers a proliferative advan-
tage under hypoxic conditions. (A) Proliferation
rates of Tsc2−/− and Tsc2+/+ MEFs under normoxic
conditions. (B) Proliferation rates under hypoxic
conditions of Tsc2+/+ and Tsc2−/− MEFs (treated or
not with rapamycin). Error bars for A and B equal
one standard deviation (n = 3). Note different Y-axis
scales in A and B. (C) Western blot analysis of
Tsc2+/+ and Tsc2−/− MEFs cultured in parallel under
hypoxic conditions for the indicated number of days.
Hypoxia regulation of mTOR by REDD1 and TSC1/TSC2
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human Redd1 (R1) or a mutant lacking its evolutionarily
conserved central region (R1dC; amino acids 96–153 out
of 232). To exclude signal from untransfected cells, and
thereby increase signal/noise ratio, a plasmid encoding
HA-S6K1 (S6K) was included in the transfection mix.
HA-S6K1 was then recovered by anti-HA immunopre-
cipitation and immunoblotted with an antibody specific
for phospho-S6K1. Wild-type Redd1, but not mutant
Redd1, down-regulated S6K1 phosphorylation (Fig. 7A).
As a control, S6K1 phosphorylation was abrogated in
cells treated with rapamycin (Fig. 7A). These data indi-
cate that Redd1 is sufficient to down-regulate S6K1
phosphorylation and that this function requires the
Redd1 central domain.
Simultaneous overexpression of two Redd orthologs in
Drosophila, Scylla and Charybdis, results in additive ef-
fects with respect to cell size (Reiling and Hafen 2004).
Since cell size in Drosophila is controlled by S6K, we
asked whether Redd2 also down-regulated S6K1 phos-
phorylation. For this purpose, we repeated these experi-
ments with HA-Redd2 (R2), alone or in combination
with Redd1. Redd2, like Redd1, inhibited S6K1 phos-
phorylation and the effects of Redd1 and Redd2 together
were possibly additive (Fig. 7A). While the same epitope
tag in Redd1 (or 2) and S6K1, combined with immuno-
precipitation, could theoretically confound our results,
qualitatively similar effects were observed when S6K1
phosphorylation was analyzed directly from cell lysates
(data not shown).
Down-regulation of S6K phosphorylation by Redd1
requires Tsc2
To ask whether Redd1 functions upstream of Tsc2, simi-
lar assays were performed in HeLa cells in which Tsc2
function was impaired using siRNA. The effect of Redd1
and Redd2 on S6K1 phosphorylation in HeLa cells trans-
fected with irrelevant siRNA (Sc; scrambled) mirrored
those observed in HEK293 cells (Fig. 7, cf. B and A). In
stark contrast, the effects of Redd1 and Redd2, alone or
in combination, on S6K1 phosphorylation were com-
pletely abrogated in cells treated with either of two dif-
ferent Tsc2 siRNAs (a and b) (Fig. 7B).
To evaluate the effects of Redd1 on endogenous (rather
than ectopic) S6K as well as S6 phosphorylation, and its
dependency on Tsc1/Tsc2 for signaling, we generated a
HA-Redd1-inducible cell line (Fig. 7C). These cells were
transfected with siRNA (as above; Sc, Tsc2 a and b) and
subsequently placed in media with tetracycline to in-
duce HA-Redd1. Redd1 induction resulted in a profound
down-regulation of endogenous S6K and S6 phosphory-
lation unless Tsc2 was down-regulated by siRNA (Fig.
7C). Therefore down-regulation of S6K phosphorylation
by Redd1 and Redd2 requires Tsc2. In addition, S6K
Figure 4. mTOR regulation by hypoxia is both AMPK and Lkb1 independent. (A) Western blot analysis of extracts of Tsc2+/+ and
Tsc2−/− MEFs treated with AICAR for the indicated periods of time. (ACC-P) Acetyl-CoA carboxylase phosphorylated at S79; (AMPK-P)
AMPK phosphorylated at T172. (B) Western blot analysis of Tsc2+/+ MEFs after 4 h of treatment with either hypoxia or AICAR. (C) In
vitro AMPK kinase assay of the same extracts used in B immunoprecipitated in antibody excess with a polyclonal anti-AMPK (
AMPK) antibody or normal rabbit IgG (IgG). Samples were normalized for protein concentration prior to immunoprecipitation. Error
bars equal one standard deviation (n = 3). Also shown are background activities of immunoprecipitates incubated in the absence of
substrate (SAMS peptide). (D) Western blot analysis of Tsc2+/+ cells pretreated or not with the AMPK inhibitor compound C and
exposed to either AICAR or hypoxia for the indicated periods of time. All cells treated with compound C were exposed to the drug for
9.5 h. (E,F) Western blot of Lkb1+/+ or Lkb1−/− MEFs treated with AICAR (E) or hypoxia (F) for the indicated periods of time.
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phosphorylation in Redd1−/− cells was down-regulated
by treatment with rapamycin (data not shown), in keep-
ing with the idea that Redd1 acts upstream of mTOR.
While we cannot formally exclude that Redd1 acts in a
parallel pathway, our data suggest that Redd1 acts up-
stream of the Tsc1/Tsc2 complex to down-regulate
mTOR function in response to hypoxia.
Discussion
The data presented here indicate that the down-regula-
tion of mTOR function by hypoxia requires Tsc1/Tsc2.
Under conditions of hypoxia, Tsc2-deficient cells fail to
down-regulate S6K phosphorylation (and activity) and
accumulate Hif abnormally. Disruption of the Tsc1/
Tsc2 complex results in increased cell proliferation un-
der hypoxic conditions. Hypoxia signaling requires nei-
ther AMPK nor Lkb1 but does require de novo transcrip-
tion and the expression of Redd1. Redd1 is necessary and
sufficient for the down-regulation of mTOR by hypoxia.
Our data reveal that mTOR regulation by hypoxia re-
quires Tsc1/Tsc2 in multiple cell types. Tsc2 was essen-
tial for hypoxia-induced mTOR down-regulation in three
different cell types, MEFs, HEK293 cells, and HeLa cells.
The requirement of Tsc2 for the down-regulation of
mTOR in multiple diverse cell types suggests that
mTOR regulation by hypoxia universally requires Tsc2.
The regulation of mTOR function by hypoxia is likely to
be important physiologically, as it occurs not only in cells
grown in tissue culture, but also in vivo (Supplementary
Fig. 1), and is likely impaired in tumors from TSC patients.
Exposure of Tsc2-deficient cells to hypoxia, in contrast
to glucose (energy) depletion (Inoki et al. 2003b), did not
result in a marked increase in cell death (determined by
trypan blue exclusion; data not shown). Instead, our
studies clearly demonstrate that loss of Tsc2, which
functions as a tumor suppressor, confers a growth advan-
tage to hypoxic cells. This phenomenon might contrib-
ute to the development of tumors in patients with tu-
berous sclerosis complex and lymphangioleiomyomato-
sis (LAM), which is also linked to Tsc2 mutations
(Carsillo et al. 2000). Moreover, it raises the possibility
that physiologically relevant levels of hypoxia in normal
tissues, in a Tsc2-dependent manner, affect cell prolif-
eration and the establishment of a post-mitotic state.
Tsc2 is involved in the down-regulation of Hif, espe-
cially under low serum conditions (Brugarolas et al.
2003) and, as shown here, in response to prolonged hy-
poxia. We and others have previously shown that in-
creased Hif levels in Tsc2-deficient cells are associated
with increased expression of Hif regulated genes includ-
ing VEGF-A, which encodes for a potent angiogenic
peptide (Nguyen-Vu et al. 2001; Brugarolas et al. 2003;
El-Hashemite et al. 2003; Liu et al. 2003). Thus, pro-
longed hypoxia in Tsc2-deficient cells will further in-
crease VEGF-A. Overproduction of VEGF-A almost
certainly explains the angiogenic nature of neoplasms
(hamartomas) observed in tuberous sclerosis complex
disease and may play a causal role in LAM, which is a
disease characterized by respiratory failure. The disease
affects young women and arises from increased prolifera-
tion of smooth muscle and lymphatics in the lung pa-
renchyma. While VEGF-A functions primarily on the
blood vessel endothelium (Scavelli et al. 2004), it might
also promote pulmonary lymphangiogenesis, thereby
contributing to the pathogenesis of LAM. Increased pul-
monary lymphangiogenesis would theoretically exacer-
Figure 5. Down-regulation of mTOR function by hypoxia
requires Redd1. (A) Western blot analysis of Tsc2+/+ MEFs
pretreated (30 min prior to initiation of the hypoxia time
course) or not, with Actinomycin D and exposed to hypoxia
for the indicated periods of time. Shown in parallel, analysis
of Tsc2+/+ cells treated with Actinomycin D for the indi-
cated periods of time. Northern blot (B) and Western blot (C)
analysis of Redd1+/+ and Redd1−/− MEFs treated with hy-
poxia for the indicated periods of time.
Figure 6. Tsc2 but not Redd1 is required for growth factor
signaling. Western blot analysis of Tsc2+/+ and Tsc2−/− MEFs (A)
or Redd1+/+ and Redd1−/− MEFs (B) after serum deprivation for
the indicated periods of time.
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bate hypoxia and establish a vicious cycle characterized
by increased Hif accumulation in Tsc2-deficient pulmo-
nary cells, leading to increased VEGF-A and lymphan-
giogenesis.
In our assays, changes in the phosphorylation of S6
(S235/236) in response to hypoxia were more robust than
changes in the phosphorylation of S6K (T389) or changes
in the amount of 4E-BP1 bound to 7mGTP. While the
importance of S6K in the phosphorylation of S6 is well
documented (Pende et al. 2004), Tsc1/Tsc2 might con-
ceivably also regulate S6 phosphorylation in an mTOR-
independent/S6K-independent manner. There is prece-
dence for Tsc1/Tsc2 having rapamycin-insensitive, and
hence probably mTOR-independent, activities (Brugaro-
las et al. 2003; Karbowniczek et al. 2004). The analysis of
S6 phosphorylation is, however, biologically relevant, as
S6 but not S6K (1 and 2) is essential for cell proliferation
(Volarevic et al. 2000; Pende et al. 2004).
Our data indicate that hypoxia signaling to Tsc1/Tsc2
requires de novo transcription and the expression of the
Redd1 gene. In keeping with published observations, we
found that Redd1 mRNA is induced by hypoxia. The
Redd1 gene contains a hypoxia response element in the
promoter, which can be recognized by Hif-1 complexes
(Shoshani et al. 2002). On the other hand, Redd1 is also
induced in response to hypoxia in Hif-1−/− ES cells, al-
beit to a lesser extent (Shoshani et al. 2002). In addition,
Hif-1 is dispensable for the down-regulation of mTOR
in response to hypoxia (Arsham et al. 2003). These data
suggest that induction of Redd1 by hypoxia can also be
mediated by other Hif- family members (such as Hif-2)
or perhaps by a Hif-independent mechanism.
Redd1 expression is sufficient to down-regulate S6K1
phosphorylation. This effect is abrogated by deleting the
conserved central region of the protein (amino acids 96–
153) and requires Tsc2. While it cannot be excluded that
Redd1 functions in a parallel pathway, the simplest
model is that Redd1 functions upstream of, and acti-
vates, Tsc1/Tsc2, which in turn inhibits mTOR. Genetic
experiments in Drosophila are consistent with this
model (Reiling and Hafen 2004).
It will be important to determine how, mechanisti-
cally, Redd1 affects Tsc1/Tsc2 function. We have thus
far been unable to detect complex formation between
Tsc1/Tsc2 and Redd1 (J. Brugarolas, unpubl.). In theory,
Redd1 might, at least indirectly, affect Tsc1/Tsc2 GAP
activity. In pilot experiments, we confirmed that anti-
Tsc2 immunoprecipitates from Tsc2+/+ cells, but not
from Tsc2−/− cells, display Rheb GAP activity. However,
no difference in GAP activity was found when Tsc2 im-
munoprecipitates from normoxic and hypoxic cells were
compared (B. Manning and J. Brugarolas, unpubl.). These
data suggest that either hypoxia does not alter the intrin-
sic GAP activity of Tsc2 or that this assay is not sensi-
Figure 7. Down-regulation of S6K1 phos-
phorylation by Redd1 and Redd2. (A) Western
blot analysis of anti-HA immunoprecipitates
(top) or whole-cell extracts (bottom) from
HEK293 cells transfected with HA-tagged ex-
pression vectors encoding Redd1 (R1), Redd1
mutant lacking central domain (R1dC), Redd2
(R2), Redd1 and Redd2 (R1 + R2), or an empty
vector (pcDNA3). HA-S6K1 (S6K) was co-
transfected where indicated. Rapamycin was
added several hours prior to cell harvest
where indicated. (B) Western blot analysis of
anti-HA immunoprecipitates (bottom) or
whole-cell extracts (top) from HeLa cells ex-
ponentially growing under serum-rich condi-
tions transfected with siRNAs (Sc, scrambled;
Tsc2, b and a) and expression vectors as in A.
Rapamycin was added several hours prior to
cell harvest where indicated. Ig(H) indicates
immunoglobulin heavy chain. (C) Western
blot analysis of HA-Redd1 inducible U2OS
cells transfected with the indicated siRNAs
and stimulated to produce Redd1 with tetra-
cycline for the indicated periods of time.
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tive enough to pick up small, but physiologically rel-
evant, changes in Tsc2 GAP activity.
While our data indicate that Tsc1/Tsc2 is necessary for
the down-regulation of mTOR after prolonged hypoxia
(several days; see Fig. 3C), it remains to be established
whether Redd1 is also required in this setting. Indeed the
early peak in Redd1 expression in response to hypoxia
suggests that Redd1 might not play a role in mTOR regu-
lation by chronic hypoxia. It is also possible that AMPK
and Lkb1, although dispensable for the acute down-regu-
lation of mTOR in response to acute hypoxia, play im-
portant roles in maintaining mTOR inhibition with pro-
longed hypoxia. Indeed, AMPK appears to be activated in
HeLa cells with prolonged hypoxia, although this acti-
vation seems to be Lkb1 independent (Supplementary
Fig. 3).
Pathways that regulate Tsc1/Tsc2 function are dis-
rupted in cancer (Brugarolas and Kaelin 2004). Conse-
quently, Redd1 might also function as a tumor suppres-
sor and be mutated in human cancers. As Redd1 is in-
volved in hypoxic signaling, but not growth factor signal-
ing, the discovery of Redd1 mutations in tumors would
emphasize the importance of hypoxia in the physiological
regulation of Tsc1/Tsc2 tumor suppressor function.
Redd1 is induced by DNA damage, heat shock, and the
p53 family member p63, in addition to being induced by
hypoxia. This suggests that Redd1 may play a role in the
regulation of mTOR by other forms of cellular stress.
DNA damage can down-regulate mTOR signaling (Tee
et al. 2003) but it is not known whether this requires
Tsc1/Tsc2 and Redd1. Since overexpression of Redd2 can
also down-regulate mTOR, situations that induce Redd2
expression would also predictably lead to the down-regu-
lation of the mTOR pathway. Both Redd1 and Redd2 are
expressed during development (Ellisen et al. 2002). How-
ever, while inactivation of the Drosophila Redd or-
thologs does not affect survival during normal develop-
ment (Reiling and Hafen 2004), it diminishes survival
under conditions of hypoxia and starvation, suggesting
that Redd1 and Redd2 might both regulate cell growth in
response to a variety of stresses.
Materials and methods
Reagents
p53−/−;Tsc2−/− and p53−/−;Tsc2+/+ MEFs, as well as Tsc1−/− and
Tsc1+/+ 3T3 mouse cells, were a gift from H. Onda and D.J.
Kwiatkowski (Brigham and Women’s Hospital, Harvard Medi-
cal School, Boston, MA); Lkb1+/+ and Lkb1−/− MEFs were a gift
from N. Bardeesy and R. DePinho (Dana-Farber Cancer Insti-
tute, Harvard Medical School, Boston, MA); pcDNA3/FLAG-
HA-Tsc2 was a gift from F. Vazquez (Johns Hopkins University,
Baltimore, MD); and pRK7/HA-S6K1 (rat II isoform) was a gift
from J. Blenis (Harvard Medical School, Boston, MA). The Hif
antibody, which recognizes both Hif-1 and Hif-2 (J. Brugaro-
las, unpubl.) was a gift from J. Pouyssegur (Institute of Signaling,
Developmental Biology and Cancer Research, Nice, France)
(Richard et al. 1999). The AMPK antibody was described previ-
ously (Hamilton et al. 2001). The remaining antibodies were
purchased from the following vendors: Sigma: Tubulin- (clone
B-5-1-2); Santa Cruz: Tsc2 (C20), HA (Y11); Covance: HA
(HA11); or Cell Signaling: phosphorylated S6 S235/236, phos-
phorylated ACC S79, phosphorylated AMPK T172, p70 S6K,
4E-BP1, and eIF-4E. 7-Methyl GTP-sepharose was from Amer-
sham. Rapamycin (Calbiochem, cat. 553210) was used at 25 nM
from a 25-µM stock solution in methanol. AICAR (Calbiochem,
cat. 123040) was used at 1 mM from a 100-mM stock solution in
water. AMPKi, compound C (Merck) was used at 5 µM from a
10-mM stock in DMSO. Actinomycin D (Sigma) was used at 5
µg/mL from a 0.5-mg/mL stock in water. Tetracycline (Sigma)
was used at 10 µg/mL from a 10 mg/mL stock in water.
Cloning
Human Tsc2 cDNA (exon 31 deletion isoform) was excised
from pcDNA3/FLAG-HA-Tsc2 with BamH1 and XbaI. The XbaI
site was blunt ended with Klenow prior to insert excision. The
insert was ligated into pBabe-puro/HA previously cut with
BamH1 and SnaBI to make pBabe/HA-Tsc2, which was con-
firmed by restriction digestion and cDNA end-sequencing.
Redd1 and Redd2 cDNAs were isolated by PCR from primary
human and murine fibroblasts, respectively, cloned into the
pcDNA3 expression vector, and sequence verified. Redd1dC
carries a deletion of amino acids 96–153 and was made by over-
lap PCR.
Tissue culture
Passage 10–18 p53−/−;Tsc2+/+ and p53−/−;Tsc2−/−, as well as 3T3
immortalized Tsc1+/+ and Tsc1−/− MEFs, were cultured in
DMEM with high glucose (Invitrogen), 10% heat-inactivated
FBS (Hyclone), and 1% P/S (Gibco), and exposed to hypoxia (In
vivo2; Biotrace) where indicated (1% oxygen, 10% carbon diox-
ide at 37°C). Growth curves were determined by counting cells
in triplicate wells sequentially for 4 d. Cell death was deter-
mined by scoring trypan blue positivity after staining with 0.4%
trypan blue (Sigma). Lbk1−/− and Redd1−/− MEFs (and respective
littermate controls) were used at an early passage (<10). For
hypoxia experiments, Lbk1−/− and Redd1−/− MEFs were cultured
in MEM (Invitrogen) or DMEM, with 2% FBS and 1% P/S. The
Tet-inducible Redd1 line was created by transfecting the T-REx-
U2OS founder line (Invitrogen) with pcDNA4/TO (Invitrogen)
carrying a Redd1 cDNA followed by clonal selection. Cells were
transfected with siRNA, split 48 h later, and treated with tet-
racycline for 24 h prior to harvest.
Retroviral transduction
Phoenix amphotropic cells were transfected with empty pBabe/
HA, or pBabe/HA-Tsc2 using Lipofectamine Plus (Invitrogen)
following manufacturer’s recommendations. Supernatant was
collected at several intervals 36 h after transfection and used to
infect exponentially growing Tsc2−/− MEFs (passage 10) in the
presence of polybrene (4 µg/mL). Cells were selected in 2 µg/mL
puromycin for 6 d and utilized for experiments for two addi-
tional passages.
SiRNA transfections
siRNA transfections were as previously described (Brugarolas et
al. 2003). For experiments involving transfection of both siRNA
and plasmids, HeLa cells were seeded at very low density and
transfected with siRNA using Oligofectamine (Invitrogen) per
manufacturer’s recommendations except that the amount of
siRNA was tripled. Approximately 48 h later, when ∼80% con-
fluent, the cells were transfected with plasmid DNA using Li-
pofectamine Plus (Invitrogen) per the manufacturer’s recom-
mendations. SiRNA sequences: Sc (5-CAAUGAGUAACAAU
CCAUUGA-3); Tsc2 (a) (5-CAAUGAGUCACAGUCCUUU
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GA-3) (Inoki et al. 2002); Tsc2 (b) (5-AAAGUUCACCUACU
GCUGGCA-3).
Western blot and immunoprecipitation assays
Western blot analysis was as previously described (Brugarolas et
al. 2003). For immunoprecipitations, cells were lysed in IP
buffer (50 mM Tris HCl at pH 7.5, 150 mM NaCl, and 0.5%
Igepal CA-630 [Sigma] supplemented with Complete Mini
[Roche] and phosphatase inhibitors [Calbiochem]) for 20 min at
4°C. The lysates were precleared with protein A sepharose (Am-
ersham), normalized for protein content, and immunoprecipi-
tated with 2–3 µg anti-HA (Y11)/mg of protein overnight at 4°C.
Immunoprecipitates were recovered on Protein A sepharose,
washed three times with IP buffer, eluted with hot SDS sample
buffer, and analyzed by SDS PAGE.
7mGTP binding assays
For 7mGTP binding assays, MEFs were lysed in IP buffer. The
lysates were precleared by centrifugation, normalized for pro-
tein content, and incubated with 7mGTP-sepharose for 2 h at
4°C. The sepharose was recovered by centrifugation, washed
with IP buffer four times, and boiled in 1× SDS loading buffer.
Eluted proteins were analyzed by SDS-PAGE on a 12% gel.
Kinase assay
AMPK kinase assays were as described with minor modifica-
tions (Hamilton et al. 2001). Briefly, exponentially growing
Tsc2+/+ MEFs were lysed in IP buffer. Lysates were normalized
for protein content prior to immunoprecipitation with AMPK
antibody (Hamilton et al. 2001) or rabbit serum IgG under an-
tibody excess conditions. Immunoprecipitates were incubated
with ATP  32P (NEN) in the presence or absence of SAMS
peptide for 25 min at 30°C. No AMP was added. Reactions were
spotted onto p81 paper and thoroughly washed with 0.75%
phosphoric acid and acetone. Radioactivity of the filters was
determined using a scintillation counter (Beckman LS 6500).
Northern blot
Total RNA was prepared from primary MEFs using RNA STAT-
60 (Tel-Test). Ten micrograms total RNA per lane was electro-
phoresed through a 6% formaldehyde/1% agarose gel, trans-
ferred to Hybond-N nylon membrane (Amersham), and hybrid-
ized to 32P-labeled murine Redd1, Redd2, and GAPDH cDNA
probes.
Animal hypoxia experiments
C57BL/6 mice 2–4 mo old were placed in the hypoxia chamber
with abundant food and drink. Oxygen concentration was
slowly decreased from 21% to 6% over 1 h. CO2 was 1% and
temperature 25°C.
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